Results 171 to 180 of about 151,746 (310)

Primary Mediastinal Myelolipoma

open access: yes, 2008
Myelolipoma is a rare mesenchymal tumor composed of an admixture of fat and bone marrow-derived hematopoietic cells. It is typically an adrenal lesion, and mediastinal location is extremely unusual. We describe a 56-year-old man with nonspecific symptoms
Sadeghipour, A.   +3 more
core  

Arrhythmias associated with immune checkpoint inhibitor therapy—A clinical perspective

open access: yesBritish Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but are associated with a growing spectrum of cardiovascular immune‐related adverse events. Among these, arrhythmias represent a rare yet potentially life‐threatening complication. ICI‐induced arrhythmias encompass a wide clinical spectrum, including atrial arrhythmias, conduction ...
Dong Wang   +4 more
wiley   +1 more source

Extent of Endobronchial Ultrasound Nodal Sampling and Risk of Pathologic N2 Upstaging in Clinical N0-N1 Non-Small Cell Lung Cancer. [PDF]

open access: yesThorac Cancer
Kim MJ   +10 more
europepmc   +1 more source

Mediastinal Tumour [PDF]

open access: yesProceedings of the Royal Society of Medicine, 1928
openaire   +3 more sources

Metabolic remodelling in anthracycline cardiotoxicity: mechanisms and therapeutic insights

open access: yesBritish Journal of Pharmacology, EarlyView.
Cardiac metabolic remodelling in anthracycline‐induced cardiomyopathy and metabolically oriented cardioprotective strategies. Schematic representation of substrate utilization, mitochondrial bioenergetic function and metabolic flexibility in the healthy heart, in anthracycline‐induced cardiomyopathy and under potential cardioprotective interventions ...
Giulia Guerra   +5 more
wiley   +1 more source

Mediastinal mayhem

open access: yesBMJ Case Reports
Ronak, Rajani   +2 more
openaire   +3 more sources

Real‐World Safety and Efficacy of Pola‐R‐CHP in Previously Untreated DLBCL: POLASTAR Interim Analysis of 500 Patients

open access: yesCancer Science, EarlyView.
In this analysis of a diverse cohort of 500 patients with previously untreated DLBCL in a real‐world clinical setting, Pola‐R‐CHP demonstrated high response rates at end‐of‐treatment, which were consistent among the overall population, in patients > 80 years and regardless of International Prognostic Index status and cell of origin subtypes.
Takahiro Kumode   +21 more
wiley   +1 more source

Home - About - Disclaimer - Privacy